Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 28, 2022 08:57 ET | Source: PolyPid Ltd.

PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

Centralized Procedure Allows for Submission of a Single Marketing Application to the European Medicines Agency that, if Approved, Would Allow D-PLEX100 to be Marketed in All EU Member States ...
September 19, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

Intends to discuss the Clinical Outcomes and Next Steps for D-PLEX100 for the Prevention of SSIs in Abdominal Surgery with the FDA and the EU Regulatory Authorities in Q1 2023 PETACH TIKVA, Israel,...
September 12, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference

Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection will be Presented During a Podium Presentation PETACH TIKVA, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) --...
September 02, 2022 08:37 ET | Source: PolyPid Ltd.

PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA Requested Pre-specified Subgroup Analysis in Subjects with Incision Lengths over...
August 30, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Presentation at the 2022 Military Health System Research Symposium

Efficacy Data of D-PLEX100 in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation PETACH TIKVA, Israel, Aug. 30, 2022 (GLOBE...
August 10, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus Royalties on Net SalesIndependent Data...
August 03, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe

PolyPid to potentially receive over $110 million in upfront and milestone payments as well as royalties on net sales ADVANZ PHARMA to receive exclusive rights to commercialize D-PLEX100 for the...
July 27, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022

PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
July 25, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting

Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation PETACH TIKVA, Israel, July 25,...
July 05, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO

PETACH TIKVA, Israel, July 05, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today...